Treatment of excessive and irregular menses by a procedure called virechan nd oral drug.
Phase 2
- Conditions
- Health Condition 1: null- ASRIGDARA (EXCESSIVE BLEEDING PER VAGINALLY)
- Registration Number
- CTRI/2018/01/011280
- Lead Sponsor
- IPGT AND RA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
A.patients having any one or two of the following features like
1.excessive per vaginal bleeding,
2.prolonged duration bleeding,
3.inter-menstrual bleeding,
4.bleeding with heavy clots
B.patients who are yogyafor virechana
Exclusion Criteria
1.age below 18 and 50 years.
2.bleeding due to polyp, erosion, cancer & fibroid.
3.bleeding followed by abortion
4.bleeding from the site other than the uterus.
5.coagulation disorders.
6.suffering from malignancies, diabetes, venereal disease.
7.patients who are Ayogya for Virechana.
8.postmenopausal bleeding
9.Hb% <8
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method cure of asrigdaraTimepoint: 4 month
- Secondary Outcome Measures
Name Time Method Relief in bleeding as compare to previousTimepoint: 4 months